Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use
Could Seize Share From Sanofi - Analysts
Sanofi’s monoclonal antibody is still expected to lead the market in respiratory syncytial virus, but Pfizer may have just overturned expectations about maternal vaccination with its product.
You may also be interested in...
Pfizer Plans For COVID Transition And RSV Vaccine Launch
The COVID-19 vaccine and treatment market is expected to evolve into more a flu-like volume and market in 2023, but will remain a "multi-billion dollar" franchise, Bourla said.
Pfizer’s RSV Vaccine Shows Efficacy In Older Adults, Setting Up Showdown With GSK
Pfizer’s bivalent vaccine candidate showed efficacy in RSV patients with multiple respiratory infection symptoms and may offer protection against the A and B strains of the virus.
Recent US FDA Breakthrough Therapy Designations, From Mass Market Vaccines To Rare Diseases
Merck’s latest pneumococcal vaccine and Pfizer’s RSV vaccine notched new BTDs, along with Zambon’s inhaled antibiotic for non-CF bronchiectasis, Acer’s vascular Ehlers-Danlos syndrome drug and Dizal’s targeted lung cancer candidate.